Neurocrine Biosciences | NBIX - Equity Capital And Reserves



Neurocrine Biosciences reported $2.69B in Equity Capital and Reserves for its fiscal quarter ending in June of 2025.


Equity Capital And Reserves Change Date
AbbVie USD 1.46B 1.86B Mar/2025
Acadia Pharmaceuticals USD 822.38M 57.14M Jun/2025
Agios Pharmaceuticals USD 1.37B 96.97M Jun/2025
ALKERMES USD 1.62B 113M Jun/2025
Alnylam Pharmaceuticals USD 250.59M 135.16M Jun/2025
Amgen USD 7.43B 1.22B Jun/2025
Biogen USD 17.63B 655.3M Jun/2025
BioMarin Pharmaceutical USD 6.03B 233.65M Jun/2025
Cytokinetics USD -737440000 471.03M Jun/2025
Dynavax Technologies USD 494.16M 36.78M Jun/2025
Exelixis USD 2.03B 97.49M Jul/2025
Gilead Sciences USD 19.67B 596M Jun/2025
Halozyme Therapeutics USD 332.75M 149.52M Jun/2025
Incyte USD 4.17B 503.34M Jun/2025
Ionis Pharmaceuticals USD 631.72M 156M Jun/2025
Neurocrine Biosciences USD 2.69B 158.6M Jun/2025
Pfizer USD 88.7B 1.64B Jun/2025
Prothena USD 324.33M 162.6M Jun/2025
Regeneron Pharmaceuticals USD 29.94B 551.3M Jun/2025
Repligen USD 1.99B 12.76M Mar/2025
Sarepta Therapeutics USD 1.36B 214.66M Jun/2025
Teva Pharmaceutical Industries USD 6.83B 572M Jun/2025
Ultragenyx Pharmaceutical USD 151.29M 7.04M Jun/2025
Vertex Pharmaceuticals USD 17.18B 679.1M Jun/2025